SAR Studies on Tetrahydroisoquinoline Derivatives: The Role of Flexibility and Bioisosterism To Raise Potency and Selectivity toward P-glycoprotein

被引:28
作者
Capparelli, Elena [1 ]
Zinzi, Laura [1 ]
Cantore, Mariangela [3 ]
Contino, Marialessandra [1 ]
Perrone, Maria Grazia [1 ]
Luurtsema, Gert [2 ]
Berardi, Francesco [1 ,3 ]
Perrone, Roberto [1 ,3 ]
Colabufo, Nicola A. [1 ,3 ]
机构
[1] Univ Bari A Moro, Dipartimento Farm Sci Farmaco, I-70125 Bari, Italy
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Nucl Med & Mol Imaging, NL-9713 GZ Groningen, Netherlands
[3] Spin Off Univ Bari A Moro, Biofordrug Srl, I-70125 Bari, Italy
关键词
MULTIDRUG-RESISTANCE; PRECLINICAL EVALUATION; CANCER; PET; ASSAYS; RADIOTRACERS; CANDIDATES; EXPRESSION; MODULATORS; INHIBITORS;
D O I
10.1021/jm501640e
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The development of P-glycoprotein (P-gp) ligands remains of considerable interest, mostly for investigating the protein's structure and transport mechanism. In recent years, many different generations of ligands have been tested for their ability to modulate P-gp activity. The aim of the present work is to perform SAR studies on tetrahydroisoquinoline derivatives in order to design potent and selective P-gp ligands. For this purpose, the effect of bioisosteric replacement and the role of flexibility have been investigated, and four series of tetrahydroisoquinoline ligands have been developed: (a) 2-aryloxazole bioisosteres, (b) elongated analogues, (c) 2H-chromene, and (d) 2-biphenyl derivatives. The results showed that both 2-biphenyl derivative 20b and elongated derivative 6g behaved as strong P-gp substrates. In conclusion, important aspects for developing potent and selective P-gp ligands have been highlighted, providing a solid starting point for further optimization.
引用
收藏
页码:9983 / 9994
页数:12
相关论文
共 27 条
[21]   Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats [J].
Muellauer, Julia ;
Karch, Rudolf ;
Bankstahl, Jens P. ;
Bankstahl, Marion ;
Stanek, Johann ;
Wanek, Thomas ;
Mairinger, Severin ;
Mueller, Markus ;
Loescher, Wolfgang ;
Langer, Oliver ;
Kuntner, Claudia .
NUCLEAR MEDICINE AND BIOLOGY, 2013, 40 (06) :755-763
[22]   Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds [J].
Palmeira, A. ;
Sousa, E. ;
Vasconcelos, M. H. ;
Pinto, M. M. .
CURRENT MEDICINAL CHEMISTRY, 2012, 19 (13) :1946-2025
[23]  
Polli JW, 2001, J PHARMACOL EXP THER, V299, P620
[24]   In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: A recommendation for probe substrates [J].
Rautio, J ;
Humphreys, JE ;
Webster, LO ;
Balakrishnan, A ;
Keogh, JP ;
Kunta, JR ;
Serabjit-Singh, CJ ;
Polli, JW .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (05) :786-792
[25]   Synthesis and Preclinical Evaluation of Novel PET Probes for P-Glycoprotein Function and Expression [J].
van Waarde, Aren ;
Ramakrishnan, Nisha K. ;
Rybczynska, Anna A. ;
Elsinga, Philip H. ;
Berardi, Francesco ;
de Jong, Johan R. ;
Kwizera, Chantal ;
Perrone, Roberto ;
Cantore, Mariangela ;
Sijbesma, Jurgen W. A. ;
Dierckx, Rudi A. ;
Colabufo, Nicola A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (14) :4524-4532
[26]   Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier [J].
Wanek, Thomas ;
Mairinger, Severin ;
Langer, Oliver .
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2013, 56 (3-4) :68-77
[27]   Small and innavative molecules as ne strategy to revert MDR [J].
Zinzi, Laura ;
Capparelli, Elena ;
Cantore, Mariangela ;
Contino, Marialessandra ;
Leopoldo, Marcello ;
Colabufo, Nicola Antonio .
FRONTIERS IN ONCOLOGY, 2014, 4